<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336883">
  <stage>Registered</stage>
  <submitdate>7/03/2012</submitdate>
  <approvaldate>15/03/2012</approvaldate>
  <actrnumber>ACTRN12612000298819</actrnumber>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety and Tolerability of Epratuzumab in Patients With Systemic Lupus Erythematosus.</studytitle>
    <scientifictitle>A phase 3, multicenter, open-label, extension study to assess the safety and tolerability of epratuzumab treatment in systemic lupus erythematosus subjects (EMBODY 4)</scientifictitle>
    <utrn />
    <trialacronym>EMBODY 4</trialacronym>
    <secondaryid>NCT01408576 Clintrials.gov</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Systemic Lupus Erythematosus</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Epratuzumab 600mg intravenous infusions delivered once a week (QW) via slow infusion for a total of 4 consecutive weeks (cumulative dose (CMD) 2400mg) over eight 12-week treatment cycles</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The percentage of subjects meeting treatment response criteria at week 48 and week 96 according to a combined response index which incorporates criteria for achievement from the BILAG, SLEDAI, and physician's global assessment of disease activity.</outcome>
      <timepoint>week 48 and week 96</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The percentage of subjects meeting treatment response criteria at all other time points assessed during the study according to a combined response index which incorporates criteria for achievement from the BILAG, SLEDAI, and physician's global assessment of disease activity.</outcome>
      <timepoint>All other time points assessed during the study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>The subject has completed double-blind study SL0009 (ACTRN12611000464965) or SL0010, or the subject has terminated prematurely at Week 16 or later in SL0009 or SL0010 due to lack of efficacy, as described in the respective protocols and would, in the opinion of the investigator, continue to benefit from continued epratuzumab treatment in SL0012. 

The subject has maintained the eligibility requirements (including concomitant medication restrictions) throughout their participation in the prior study

Woman of childbearing potential using an acceptable method of birth control</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subject has active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring BILAG level A disease

Subject has active, severe, SLE disease activity which involves the renal system defined by BILAG renal level A activity

Evidence of an immunosuppressive state

Subjects with a history of chronic infections, including but not limited to subjects with concurrent acute or chronic viral hepatitis B or C

Subjects with substance abuse/dependence or other concurrent medical conditions

Subjects with significant hematologic abnormalities

History of malignant cancer

Subject has used the prohibited medications</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Subjects who complete the Phase 3, double-blind, placebo-controlled study, SL0009, or terminate prematurely (at Week 16 or later) due to lack of efficacy, are eligible to enroll in this open-label extension study.

To enroll a subject (Visit 1), the investigator will call the IVRS and provide brief details about the subject to be enrolled. Each subject will keep the subject number assigned at Screening in SL0009, which serves as the subject identifier throughout SL0012. All subjects will receive epratuzumab 600mg infusions delivered QW for a total of 4 consecutive weeks (CMD 2400mg) repeated every 12 weeks.</concealment>
    <sequence>This study is open label and all subjects receive the same treatment. The interactive voice response system (IVRS) is responsible for issuing subject kits of epratuzumab, as appropriate, according to the visit schedule.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>20/07/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3145</postcode>
    <postcode>3168</postcode>
    <postcode>4558</postcode>
    <postcode>2050</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Wurttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Democratic People's Republic Of</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape Province</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan, Province Of China</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Essex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>South Yorkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Yorkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>East Sussex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dorset</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Uttar Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Lucknow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Kwa-Zulu Natal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>UCB Inc</primarysponsorname>
    <primarysponsoraddress>1950 Lake Park Drive, Smyrna GA 30080, USA</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>UCB Inc.</fundingname>
      <fundingaddress>1950 Lake Park Drive, Smyrna GA 30080, USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 3, multicenter, open-label, extension study to evaluate the safety, tolerability, efficacy, and immunogenicity of long-term epratuzumab treatment in subjects with SLE.
Subjects who complete 1 of the Phase 3, double-blind, placebo controlled studies, SL0009 or SL0010, or terminate prematurely (at Week 16 or later) due to lack of efficacy, are eligible to enroll in SL0012. 
The study consists of an Open-Label Treatment Period and a Safety Follow-Up Visit. During the Open-Label Treatment Period, all subjects will receive epratuzumab 600mg delivered QW via slow iv infusion for a total of 4 consecutive weeks (CMD 2400mg) over eight 12 week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48 (Year 1), 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87 (Year 2) [96 weeks total duration]). A Safety Follow-Up Visit will occur approximately 4 weeks after Week 96 (ie, no later than Week 100) for subjects who complete the study, or 13 weeks after the final dose of study drug for subjects who discontinue early.
Study drug treatment is in addition to the subjects existing standard care of oral corticosteroids and any immunosuppressants or antimalarials continued from Baseline in the subjects prior study.</summary>
    <trialwebsite>www.embodyprogram.com</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Leading Ethics Committee: CPP  - Ile de France V1</ethicname>
      <ethicaddress>10, Pavilion Jacquard, 47, Bd De L'Hopital 
75651 Paris Cedex 13</ethicaddress>
      <ethicapprovaldate>21/01/2011</ethicapprovaldate>
      <hrec>CPP no: 113-10</hrec>
      <ethicsubmitdate />
      <ethiccountry>France</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prof. Dr. J-M Maloteaux</ethicname>
      <ethicaddress>Avenue Hippocrate 53-14, Tour Harvey -Niveau 0, 1200 Bruxelles;</ethicaddress>
      <ethicapprovaldate>21/02/2011</ethicapprovaldate>
      <hrec>OM 003</hrec>
      <ethicsubmitdate />
      <ethiccountry>Belgium</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Eticka Komise Revmatologickeho ustav</ethicname>
      <ethicaddress>Na Stupi4, 128-50 Praha 2</ethicaddress>
      <ethicapprovaldate>21/12/2010</ethicapprovaldate>
      <hrec>6044/2010-</hrec>
      <ethicsubmitdate />
      <ethiccountry>Czech Republic</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>National Institute of Pharmacy</ethicname>
      <ethicaddress>H-1051, Budapest, Zrinyi03
H-1372 Budapest, POB:450</ethicaddress>
      <ethicapprovaldate>8/02/2011</ethicapprovaldate>
      <hrec>OGYI/54703-6/2010</hrec>
      <ethicsubmitdate />
      <ethiccountry>Hungary</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Barzilai Medical Center</ethicname>
      <ethicaddress>Ben-Gurion University of the Negen</ethicaddress>
      <ethicapprovaldate>2/03/2011</ethicapprovaldate>
      <hrec>1703</hrec>
      <ethicsubmitdate />
      <ethiccountry>Israel</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Helsinki Committee of Bnai Zion Medical Center</ethicname>
      <ethicaddress>Bnai Zion Medical Center, 43 Golomb St. , Haifa 31048,</ethicaddress>
      <ethicapprovaldate>21/01/2011</ethicapprovaldate>
      <hrec>0149-10-BNZ</hrec>
      <ethicsubmitdate />
      <ethiccountry>Israel</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Pharma Ethics Ltd</ethicname>
      <ethicaddress>123 Amcor Road, Lyttelton Manor 0157</ethicaddress>
      <ethicapprovaldate>7/03/2011</ethicapprovaldate>
      <hrec>11014093</hrec>
      <ethicsubmitdate />
      <ethiccountry>South Africa</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>CEIC de Euskadi</ethicname>
      <ethicaddress>Comittico de Investigacin Clinica de la Comunidad Aut noma del Pas Vasco. CEIC-E, Direccin de Farmacia del Departamento de Sanidad, C/ Donostia - San Sebastin, 1, 01010 Vitoria - Alava</ethicaddress>
      <ethicapprovaldate>14/02/2011</ethicapprovaldate>
      <hrec>NAP</hrec>
      <ethicsubmitdate />
      <ethiccountry>Spain</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Central Ethics Commission of Ministry of Health of Ukraine</ethicname>
      <ethicaddress>Vul. Narodnogo opolchennia, 5, Kyiv, 03680 MSP</ethicaddress>
      <ethicapprovaldate>16/03/2011</ethicapprovaldate>
      <hrec>#5.12-282/KE</hrec>
      <ethicsubmitdate />
      <ethiccountry>Ukraine</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Ethics Committee  Shalby Hospital</ethicname>
      <ethicaddress>Shalby Hospital, Opp. Karnavati Club, S.G. Road, Ahmedabad-380015,Gujarat</ethicaddress>
      <ethicapprovaldate>9/02/2011</ethicapprovaldate>
      <hrec>NAP</hrec>
      <ethicsubmitdate />
      <ethiccountry>India</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Schulman Associates IRB, Inc.</ethicname>
      <ethicaddress>4290 Glendale-Milford Road
Cincinnati, OH 45242</ethicaddress>
      <ethicapprovaldate>10/12/2010</ethicapprovaldate>
      <hrec>201066940</hrec>
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Betsy Smith</name>
      <address>Clinical Project Manager 
UCB BioSciences, Inc.
8010 Arco Corporate Drive, Suite 100
Raleigh, NC 27617</address>
      <phone>+1 919 767 2619</phone>
      <fax />
      <email>betsy.smith@ucb.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dulce Lauterbach</name>
      <address>PAREXEL International Pty Ltd 
Suite B Level 6, 15 Talavera Road 
North Ryde NSW 2113</address>
      <phone>+61 2 8870 3100 (reception) +61 2 8870 3191 (direct)</phone>
      <fax />
      <email>dulce.lauterbach@parexel.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melissa Dunn</name>
      <address>C/O PAREXEL International Pty Ltd 
Suite B Level 6, 15 Talavera Road 
North Ryde NSW 2113</address>
      <phone>+61 8 8288 0544</phone>
      <fax>+61 8 8288 0599</fax>
      <email>melissa.dunn@parexel.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>